drugset / Trial / NCT00861484

Proof of Mechanism in ELT

NCT00861484 ↗

Phase 1 Completed 33 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE

Timeline

Start
2008-11-26
Primary completion
2009-12-11
Completion
2009-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK958108 Small molecule 3 mg Oral

Indications